Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Raul Rodriguez
|
| gptkbp:collaboratedWith |
gptkb:AstraZeneca
gptkb:Bristol_Myers_Squibb |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
immunology
oncology hematology |
| gptkbp:fostamatinibBrandName |
Tavalisse
|
| gptkbp:founded |
1996
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rigel Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:fostamatinib
|
| gptkbp:numberOfEmployees |
approximately 100-200
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchArea |
rare diseases
autoimmune diseases |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
RIGL
|
| gptkbp:TavalisseIndication |
chronic immune thrombocytopenia
|
| gptkbp:website |
https://www.rigel.com/
|
| gptkbp:bfsParent |
gptkb:South_San_Francisco,_California,_USA
|
| gptkbp:bfsLayer |
7
|